Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon National Health Strategy-Vision 2030



Lebanon National Health Strategy – Vision 2030- Two Year Review
Lebanon National Health Strategy – Vision 2030- One Year Review

Introduction

In January 2023, the Ministry of Public Health (MoPH) launched its National Health Strategy: Vision 2030. Vision 2030 set out the framework for a sustained and modernized recovery of the health sector and intended to address the challenges of leading a burned-out health system. Through this strategy, and under the leadership of the MoPH, the different partners of the health sector joined efforts to respond to the escalating unmet health needs and participate in building a stronger, more resilient health system.

Over the past year, the National Health Strategy has made significant strides in enhancing the overall well-being of the population. The multifaceted approach has addressed key issues such as human resources shortage, challenged healthcare accessibility, and the massive gaps in health financing. Despite the multiple predicaments in the country, including the ongoing war and hostilities; the economic collapse and financial meltdown; the extended refugee crisis with its associated increased demand for scarce health resources; and disease outbreaks such as cholera; the health sector remained steady, and determined in achieving progress across the objectives outlined in the National Health Strategy. The National Health Strategy’s commitment to fostering advanced governance and financing mechanisms, investing in essential public health functions, strengthening primary healthcare, capacitating human resources, and embracing digital health technologies is expected to result in an advanced, more equitable, more inclusive, and more sustainable healthcare delivery.(Read More...)
 
Lebanon National Health Strategy: Vision 2030
 
Executive Summary

Lebanon is passing through one of the most severe and complex crises in its recent history, caused by the interplay of political turbulence, socioeconomic meltdown, and the lingering COVID-19 pandemic. Regionally, conflict and instability continue to result in the influx of refugees, which constitute now around one third of the Lebanese population.

The intertwined crises Lebanon has been suffering from unmasked the effects of pre-existing health system inefficiencies, including the predominance of tertiary care over preventive and primary care; a weakened public health sector; a pluralistic financing system; and a supply-induced demand with unsustainable and unrealistic expectations. The synergistic effects of these crises amplified the malfunctioning of a disrupted health system, rendering a system notorious for its resilience at the verge of a breakdown. As a result, the ability to respond to the increased needs of a growing population was deterred. Equitable access to care was exceptionally difficult for people with vulnerabilities. Worsening in health outcomes was noted at many fronts: life expectancy, maternal mortality, under 5 mortality, and childhood vaccination. Previously forgotten diseases such as diphtheria, tetanus, and most recently cholera re-emerged, and the health gains of previous years have started to fade away.

The multifaceted crisis has also severely impacted access to and utilization of healthcare services. The percentage of households with difficulty accessing health care rose from 25% to 36% within around 4 months during the year 2020. Hospitalizations, particularly for surgeries, diminished by 30% in 2021, and the average monthly hospitalization days decreased by 25%. The cost of treatments, medical consultations, or transportation to health facilities have become prohibitive to many, resulting in delayed presentation of patients for medical attention, who at many times presented with decompensated or non-salvageable conditions. Duly, challenged access to specialized healthcare was coupled with an exponential increased demand on the services provided by the Primary Health Care Network. With crisis, an opportunity has emerged for repositioning primary health care as a gateway for affordable, quality promotive, preventive, and primary health services, and for moving closer towards achieving Universal Health Coverage.

The recent drain of human resources particularly those with high competencies and specialization has become an increasing concern, with more than 20% of nurses and around 40% of doctors having already left the country. Additionally, the layoffs, salary cuts and closures of pharmacies and the reduced activities of hospitals which accompanied the economic crisis, deleteriously affected the healthcare workforce. This shortage in qualified human resources endangered the quality and availability of health care services.

The pharmaceutical sector was also hit hard by the crisis. In 2020, the government’s policy of relying on external sources for medications and medical supplies, coupled the economic crisis, led to drops in imports, resulting in severe market shortages. This has paved the way to hoarding, smuggling, black market practices, and the entry of illegal, low-quality drugs and supplies into the country.(Read More...)


ِAnnexes:
    ...
    149
    ...
ATC Name B/G Ingredients Dosage Form Price
B05BB02 DEXTROSE 5% & SODIUM CHLORIDE 0.9% G Sodium chloride - 0.9g/100ml, Dextrose, H2O - 5g/100ml Injectable solution 189,262 L.L
C08CA04 NICARDIPINE ARROW G Nicardipine chlorhydrate - 10mg/10ml 10mg/10ml Injectable solution 2,590,928 L.L
C09DX01 VIOSTAN AM PLUS 160/5/25 G Valsartan - 160mg, Amlodipine - 5mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,196,020 L.L
D05AA VASELINE ICHTYOLEE G Ichthyamol - 10% 10% Ointment 103,668 L.L
J01DH51 IMILASTIN G Imipenem - 500mg, Cilastatin - 500mg Injectable powder for solution 5,869,189 L.L
J05AF10 ENTRILIV G Entecavir - 0.5mg 0.5mg Tablet, film coated 19,165,898 L.L
M01AB05 OLFEN 75MG G Diclofenac sodium - 75mg 75mg Injectable solution 334,617 L.L
N01AH06 REMIFENTANIL MEDIS G Remifentanil (HCl) - 1mg 1mg Injectable powder 1,101,951 L.L
N03AX12 PMS-GABAPENTIN G Gabapentin - 400mg 400mg Capsule 1,071,042 L.L
N05BA12 ALPROX G Alprazolam - 0.5mg 0.5mg Tablet 383,955 L.L
R05X COLDIN-H G Paracetamol - 300mg, Mepyramine maleate - 15mg, Noscapine - 10mg Capsule 386,515 L.L
V03AF03 CALCIUMFOLINAT EBEWE G Calcium folinate - 100mg/10ml 100mg/10ml Injectable solution 1,289,872 L.L
A03FA03 FARCOTILIUM G Domperidone - 5mg/5ml 5mg/5ml Suspension 115,570 L.L
A10BB12 AMEPRIDE G Glimepiride - 4mg 4mg Tablet 215,015 L.L
B05BB02 DEXTROSE 5% & SODIUM CHLORIDE 0.9% G Sodium chloride - 0.9g/100ml, Dextrose, H2O - 5g/100ml Injectable solution 182,720 L.L
C08CA04 NICARDIPINE MEDIS G Nicardipine chlorhydrate - 10mg/10ml 10mg/10ml Injectable solution 1,295,464 L.L
D05AX52 BETA-CAL G Calcipotriol (monohydrate) - 50mcg/g, Betamethasone (dipropionate) - 0.5mg/g Ointment 1,574,983 L.L
G03DB08 DIENOSIS G Dienogest - 2mg 2mg Tablet 2,822,069 L.L
J01AA07 TETRACYCLINE G Tetracycline HCl - 250mg 250mg Capsule 3,906,998 L.L
J01DH51 IMIPENEM-CILASTATIN LABATEC G Imipenem (monohydrate) - 500mg, Cilastatin (sodium) - 500mg Injectable powder for solution 8,922,845 L.L
J05AF10 HEPCAVIR 0.5 G Entecavir monohydrate - 0.5mg 0.5mg Tablet, film coated 18,998,515 L.L
L01DC01 BLEO-CELL G Bleomycin (sulfate) - 15mg 15mg Injectable powder for solution 3,054,554 L.L
M01AB05 VOLDEN G Diclofenac sodium - 75mg/3ml 75mg/3ml Injectable solution 422,351 L.L
N03AX12 GABATREX G Gabapentin - 100mg 100mg Capsule 292,958 L.L
N05BA12 PAZOLAM G Alprazolam - 0.5mg 0.5mg Tablet 563,070 L.L
P02CA03 ALBENDA G Albendazole - 100mg/5ml 400mg/20ml Suspension 129,009 L.L
R06AA02 DIPHENIST G Diphenhydramine HCl - 50mg/ml 50mg/ml Injectable solution 6,977,230 L.L
V03AF03 EUROFOLIC G Folic acid as Calcium Folinate Hydrate - 100mg/10ml 10mg/ml Injectable solution 5,872,592 L.L
A03FA03 MOTIDOL ODT G Domperidone - 10mg 10mg Tablet, orodispersible 259,810 L.L
A10BB12 DIAMERIL G Glimepiride - 4mg 4mg Tablet 322,522 L.L
    ...
    149
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025